EMA Recommends Extending Indications for Pembrolizumab and Adopted a New Pharmaceutical Form Along with a New Route of Administration By Ogkologos - October 3, 2025 245 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns treatment of patients with resectable locally advanced head and neck squamous cell carcinoma Source RELATED ARTICLESMORE FROM AUTHOR Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC EMA Recommends Granting a Marketing Authorisation for Poherdy Whole-Genome Sequencing Meets Diagnostic Requirements in Routine Practice for Patients with Solid Cancers MOST POPULAR EMA Recommends Extension of Indications for Darolutamide January 31, 2023 Mosunetuzumab Plus Polatuzumab Vedotin Shows Promise for Patients with Aggressive Relapsed... December 21, 2023 ¿Puede el uso de aceites esenciales ayudar a tratar el cáncer... June 23, 2022 Should People with Cancer and Cancer Survivors Get the Flu Vaccine? September 2, 2020 Load more HOT NEWS Molecular Determinants of Sotorasib Efficacy in Patients with Advanced KRASG12C-mutated NSCLC Population Mortality from NSCLC in the US Fell Sharply Due to... Advances in Gynaecological Cancer Research Could Change the Treatment Landscape Neoadjuvant Histotype-Tailored Treatment with Trabectedin Not Inferior to Standard Chemotherapy with...
